No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus

European Journal of Epidemiology

Volumn 28, Issue 8, 2013, Pages 705-707

  Pellegrino, Paolo ^a   Carnovale, Carla ^a   Perrone, Valentina ^a   Antoniazzi, Stefania ^a   Pozzi, Marco ^b   Clementi, Emilio ^a,b   Radice, Sonia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LETTER; MULTIPLE SCLEROSIS; PAPILLOMAVIRUS INFECTION; VACCINATION;

ADOLESCENT; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MULTIPLE SCLEROSIS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 84884350679     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-013-9830-y     Document Type: Letter

References (5)

1. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750-7.
2. Gold MS, McIntyre P. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sex Health. 2010;7(3):320-4.
3. Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler. 2009;15(1):116-9.
4. Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry. 2011;82(11):1296-8.
5. Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J. 2007;26(11):979-84.